Bevacizumab in the treatment of breast cancer: Rationale and current data

Oncologist

Volumn 9, Issue SUPPL. 1, 2004, Pages 43-49

  Rugo, Hope S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bevacizumab; Breast cancer; Monoclonal antibodies; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; LIGAND; NAVELBINE; PACLITAXEL; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; EPISTAXIS; GENE OVEREXPRESSION; HUMAN; HYPERTENSION; METASTASIS; OPEN STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; SOLID TUMOR; THROMBOSIS;

EID: 2942621888     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-suppl_1-43     Document Type: Conference Paper

References (39)

1. Ménard S, Fortis S, Castiglioni F et al. HER2 as a prognostic factor in breast cancer. Oncology 2001;61(suppl 2):67-72.
2. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648.
3. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726.
4. Slamon DJ, Leyland-Jones B, Shak S et al. Concurrent administration of anti-HER2 monoclonal antibody and first-line chemotherapy for HER2-overexpressing metastatic breast cancer: a phase III, multinational, randomized controlled trial. N Engl J Med 2001;344:783-792.
5. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
6. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994;79:185-188.
7. Gasparini G, Toi M, Gion M et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997;89:139-147.
8. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599.
9. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999;56:794-814.
10. Brown LF, Berse B, Jackman RW et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995;26:86-91.
11. Relf M, LeJeune S, Scott PA et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963-969.
12. Hyder SM, Murthy L, Stancel GM. Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res 1998;58:392-395.
13. Ruohola JK, Valve EM, Karkkainen MJ et al. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol 1999;149:29-40.
14. Nakamura J, Savinov A, Lu Q et al. Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethyl-benz(a)anthracene-induced rat mammary tumors. Endocrinology 1996;137:5589-5596.
15. Pegram MD, Reese DM. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin Oncol 2002;29(suppl 11):29-37.
16. Sledge GW Jr. Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects. Semin Oncol 2002;29(suppl 11):104-110.
17. Linderholm B, Lindh B, Beckman L et al. The prognostic value of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) and associations to first metastasis site in 1307 patients with primary breast cancer. Proc Am Soc Clin Oncol 2001;20:4a.
18. Foekens JA, Peters HA, Grebenchtchikov N et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001;61:5407-5414.
19. Weidner N, Semple JP, Welch WR et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
20. Toi M, Inada K, Suzuki H et al. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 1995;36:193-204.
21. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. The Oncologist 2000;5(suppl 1):37-44.
22. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002;94:883-893.
23. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-844.
24. Lee CG, Heijn M, di Tomaso E et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions Cancer Res 2000;60:5565-5570.
25. Netti PA, Hamberg LM, Babich JW et al. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Acad Sci USA 1999;96:3137-3142.
26. Borgstrom P, Gold DP, Hillan KJ et al. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999;19:4203-4214.
27. Sweeney CJ, Miller KD, Sissons SE et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61:3369-3372.
28. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-850.
29. Margolin K, Gordon MS, Holmgren E et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001;19:851-856.
30. Langmuir VK, Cobleigh MA, Herbst RS et al. Successful long-term therapy with bevacizumab (Avastin™) in solid tumors. Proc Am Soc Clin Oncol 2002;21:9a.
31. Sledge GW, Cobleigh MA, Langmuir VK et al. A phase II dose-escalation trial of bevacizumab (Avastin™) in previously treated metastatic breast cancer. J Clin Oncol 2003 (in press).
32. Burstein HJ, Parker LM, Savoie J et al. Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. Breast Cancer Res Treat 2002;76(suppl 1):S115.
33. Miller KD, Rugo HS, Cobleigh MA. Phase III trial of capecitabine (Xeloda®) plus bevacizumab (Avastin™) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. Breast Cancer Res Treat 2002;76(suppl 1):S37.
34. Browder T, Butterfield CE, Kraling BM et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-1886.
35. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-1047.
36. Hillan KJ, Koeppen HKW, Tobin P et al. The role of VEGF expression in response to bevacizumab plus capecitabine in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2003;22:191.
37. Bergsland E, Dickler MN. Maximizing the potential of bevacizumab in cancer treatment. The Oncologist 2004;9(suppl 1):36-42.
38. Li CY, Shan S, Huang Q et al. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 2000;92:143-147.
39. Harmey JH, Bouchier-Hayes D. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. Bioessays 2002;24:280-283.